Other innovations
If your innovation doesn’t fit any of the active categories then this is the place to submit your innovation for feedback and the opportunity for wider adoption across the region.

Ideas (Innovation and adoption)

Innovation 'Elevator Pitch':
Revamil Melginate Dressing:
  • 5x5cm & 10x10cm
  • 100% pure & controlled enzyme rich honey
  • Anti-microbial protection stimulates wound healing
  • Batch consistency with a low Ph 3.5
  • Suitable for a broad range of wound indications
  • Suitable for all ages & diabetics
Overview of Innovation:
Revamil Melginate is a calcium alginate sheet impregnated with pure honey and produced under controlled conditions. The carefully controlled production process guarantees that Revamil Melginate with honey does not contain any traces of pesticides and that the same quality can be reproduced consistently. When Revamil Melginate is applied on exudating wounds a gel is formed by absorption of wound fluid which protects the wound against maceration.
  • High moisture absorption capacity for use on low to high exudating wounds.
  • Enzyme rich Revamil honey offers protection against wound infections.
  • Revamil Melginate’s fast acting gel formation helps maintain a moist wound environment.
  • Revamil Melginate borders are not impregnated with honey, to maintain a high absorption capacity, preventing maceration
  • The alginate gelling facilitates easy dressing change because it does not adhere to wound, therefore, no residues remain in the wound after removal.
  • Revamil Melginate can be used on the following wound types:infected wounds, surgery and radiation induced oncological wounds, exudating wounds, bed sores, ulcers and 1st and 2nd degree burns.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Innovation and adoption / Person centred care
Benefit to NHS:
In the clinical testing carried out Revamil honey killed Bacillus subtilis, Escherichia coli and Pseudomonas aeruginosa within 2 hours, whereas manuka honey, the comparator dressing, widely used within the NHS and had such rapid activity, only against B. subtilis. After 24 hours of incubation, both honeys killed all tested bacteria, including methicillin-resistant Staphylococcus aureus.
 
This would greatly improve wound healing outcomes and allow the patient to move along the wound healing pathway quicker as Revamil honey kills bioburden more rapidly within the wound site. The outcome meaning less dressing changes, reduced nursing time and greater patient comfort and efficacy.

Revamil honey dressing are 100% pure honey dressing and costings verses other 100% pure honey dressings and non-honey dressing Revamil is priced very favourably and can offer both CCG and Trust monitory savings.
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Case studies have been performed by Georgina Rostron tissue viability nurse Wigan, Warrington & Leigh community, using Revamil Melginate in a leg ulcer clinic on the treatment of several lower leg wounds, using a varied patient group.
 
The case studies demonstrate the success of using Revamil Melginate dressings on a variety of difficult and costly wounds within a community setting. The impact of such success using Revamil Melginate can lead to patient’s wellbeing and health benefiting from quicker healing times, reduced malodour and long-term psychological effects that stagnant painful wounds have on patients. Revamil Melginate dressing use can therefore support local health boards in cost efficiency and allow, where appropriate, an earlier return to work for the patient.
 
As a company, we have also had Revamil Melginate tested for the absorbency vs two of our closest competitors at the SMTL facilities in Newport South Wales. Revamil Melginate dressing over ten separate tests was the only honey calcium dressing to show superiority, our two competitor dressing readings at every test indicated a minus absorbency result.
Current and planned activity: 
Currently underway:
  • Wigan, Warrington & Leigh – Trial tissue viability
  • Barnsley Community – Trial tissue viability
  • Plymouth community – Trial tissue viability
  • Kent community – Trial tissue viability
We are seeking West Midlands partners to assist with a clinical evaluation for our UK evidence base, taking a holistic view of the economic impact from a department (Trust) and patient perspecitve.

 
Return on Investment (£ Value): 
low
Return on Investment (Timescale): 
2 years
Ease of scalability: 
2
Read more
Hide details
Clare Chesworth 13/11/2019 - 16:05 Publish 1 comment
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Revamil Gel 100% Pure Honey:
  • Sizes: 18g tube
  • 100% pure Revamil honey
  • Not contra-indicated for diabetic patients
  • Low 3.5 PH balance
  • Can be used for 3 months after opening (same patient)
  • Suitable for all age groups
  • No pesticides or parabens

 
Overview of Innovation:
Revamil hydrophilic wound gel (18g) consists of 100% pure, medicinal honey with a high enzyme content and a low ph. The carefully controlled production process guarantees that Revamil wound gel does not contain any traces of pesticides or parabens and that the same quality can be reproduced consistently.

Revamil gel supports wound healing through antibacterial protection and is particularly suitable for chronic and infected wounds.
  • Revamil wound gel creates a moist wound environment which stimulates healing.
  • Revamil wound gel neutralises wound odours.
  • Revamil wound gel creates a protective layer over the wound.
  • Revamil wound gel can be used on the following wound types:Chronic wounds, infected wounds, acute wounds, deep wounds, surgical oncological wounds, radiation induced oncological wounds, 1st and 2nd degree burns.
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Innovation and adoption / Person centred care
Benefit to NHS:
In the clinical testing carried out Revamil honey killed Bacillus subtilis, Escherichia coli and Pseudomonas aeruginosa within 2 hours, whereas manuka honey, the comparator dressing, widely used within the NHS and had such rapid activity, only against B. subtilis. After 24 hours of incubation, both honeys killed all tested bacteria, including methicillin-resistant Staphylococcus aureus.
 
This would greatly improve wound healing outcomes and allow the patient to move along the wound healing pathway quicker as Revamil honey kills bioburden more rapidly within the wound site. The outcome meaning less dressing changes, reduced nursing time and greater patient comfort and efficacy.

Revamil honey dressing are 100% pure honey dressing and costings verses other 100% pure honey dressings and non-honey dressing Revamil is priced very favourably and can offer both CCG and Trust monitory savings.
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Case studies have been performed by Professor Steve Jeffrey, Burns and Plastics, Q.E Hospital, Birmingham, using Revamil gel in the treatment of several burns on a varied patient group.
 
This article was published in the BJN (March 2019) and demonstrated the success of using Revamil gel dressings on a variety of burns patients within a hospital setting. The impact of such success can lead to patient’s wellbeing and health benefiting from quicker hospital discharge times as well as accelerated wound healing, reduced scaring and long-term psychological effects that stagnant painful wounds have on patients. Revamil gel dressing use can therefore support local health boards in cost efficiency and allow, where appropriate, an earlier return to work for the patient.
Current and planned activity: 
Currently underway:
  • Manchester Children’s Hospital – Trial of 50 patients (Burns)
  • Royal Preston Hospital – Trial burns unit (adults)
  • Stafford community – Trial tissue viability
  • Plymouth community – Trial tissue viability
  • Kent community – Trial tissue viability
We are seeking West Midlands partners to assist with clinical evaluation to create a UK evidence base, taking a holistic view of the economic impact from a department (Trust) and patient perspective.
Return on Investment (£ Value): 
low
Return on Investment (Timescale): 
2 years
Ease of scalability: 
2
Read more
Hide details
Clare Chesworth 13/11/2019 - 15:56 Publish 1 comment
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Revamil Gauze:
  • Sizes: 5x5, 8x8 10x10 and 10x20
  • 100% pure Revamil honey
  • Not contra-indicated for diabetic patients
  • Low 3.5 PH balance
  • Pliable, easy to apply and remove
  • Suitable for all age groups
  • Lightweight & comfortable
Overview of Innovation:
Revamil Gauze contains 100% pure Revamil honey. A measured amount of Revamil honey has been impregnated with the pliant poly-acetate dressing. Revamil Gauze is lightweight, does not adhere to the wound, ease of application and removal, thus providing patient comfort and a reduction in nursing time.

Revamil wound dressing can be used to treat a varied wound type such as, chronic, diabetic ulcers, infected wounds, acute wounds, surgical oncological wounds, radiation induced oncological wounds and minor (first- and second-degree) burns.

Revamil wound dressings create a moist wound environment which stimulates healing as well as neutralising wound odours which occur due to bacteria within the wound environment.

Revamil Wound Dressing characteristics:
  • 100% pure & controlled, enzyme rich honey
  • Anti-bacterial protection that stimulates wound healing
  • Batch consistence with a low Ph 3.5
  • Suitable for a broad range of wound indications
  • Suitable for all ages
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Innovation and adoption / Person centred care
Benefit to NHS:
In the clinical testing carried out Revamil honey killed Bacillus subtilis, Escherichia coli and Pseudomonas aeruginosa within 2 hours, whereas manuka honey, the comparator dressing, widely used within the NHS and had such rapid activity, only against B. subtilis. After 24 hours of incubation, both honeys killed all tested bacteria, including methicillin-resistant Staphylococcus aureus.
 
This would greatly improve wound healing outcomes and allow the patient to move along the wound healing pathway quicker as Revamil honey kills bioburden more rapidly within the wound site. The outcome meaning less dressing changes, reduced nursing time and greater patient comfort and efficacy.

Revamil honey dressing are 100% pure honey dressing and in regard to pricing verses other 100% pure honey dressings and non-honey dressing Revamil is priced very favourably and can offer both CCG and Trust monitory savings.
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Case studies have been performed by Professor Steve Jeffrey, Burns and Plastics, Q.E Hospital, Birmingham, using Revamil gauze in the treatment of several burns on a varied patient group.
 
This article was published in the BJN (March 2019) and demonstrated the success of using Revamil gauze dressings on a variety of burns patients within a hospital setting. The impact of such success can lead to patient’s wellbeing and health benefiting from quicker hospital discharge times as well as accelerated wound healing, reduced scaring and long-term psychological effects that stagnant painful wounds have on patients. Revamil gauze dressing use can therefore support local health boards in cost efficiency and allow, where appropriate, an earlier return to work for the patient.
Current and planned activity: 
Currently underway:
  • Manchester Children’s Hospital – Trial of 50 patients (Burns)
  • Royal Preston Hospital – Trial burns unit (adults)
  • Stafford community – Trial tissue viability
  • Plymouth community – Trial tissue viability
  • Kent community – Trial tissue viability
We are seeking West Midlands partners to assist with clinical evaluation to create a UK evidence base taking a holistic view of the economic impact from a department (Trust) and patient perspective.
 
Return on Investment (£ Value): 
low
Return on Investment (Timescale): 
2 years
Ease of scalability: 
2
Read more
Hide details
Clare Chesworth 13/11/2019 - 15:49 Publish 4 comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Revamil Balm:
  • Size: 15g tube
  • 25% pure Revamil honey per tube
  • Not contra-indicated for diabetic patients
  • Low 3.5 PH balance
  • Can be used for 3 months after opening (same patient)
  • Suitable for all age groups
  • No pesticides or parabens
Overview of Innovation:
Revamil Balm is a combination of a skin-protecting, neutral ointment combined with enzyme rich medical grade pure honey. The ointment has both effective wound-healing and antibacterial properties due to its high honey content. Revamil Balm is kind to the skin and is primarily suitable for the treatment of surface wounds, such as grazes and dermatological conditions such as eczema.
  • Revamil Honey creates a moist wound environment which stimulates healing
  • Revamil neutralises wound odours, wound odour may occur due to bacteria within the wound environment
  • Revamil balm does not leave a sticky residue
Revamil Balm can be used on the following wound types:
  • Superficial wounds and dermatological conditions
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Innovation and adoption / Person centred care
Benefit to NHS:
In the clinical testing carried out Revamil honey killed Bacillus subtilis, Escherichia coli and Pseudomonas aeruginosa within 2 hours, whereas manuka honey, the comparator dressing, widely used within the NHS and had such rapid activity, only against B. subtilis. After 24 hours of incubation, both honeys killed all tested bacteria, including methicillin-resistant Staphylococcus aureus.
 
This would greatly improve wound healing outcomes and allow the patient to move along the wound healing pathway quicker as Revamil honey kills bioburden more rapidly within the wound site. The outcome meaning less dressing changes, reduced nursing time and greater patient comfort and efficacy.

Revamil honey balm dressing have 25% pure honey in each tube and is suitable for patients with sensitive wounds or unable to tolerate a secondary dressing. The scope in which Revamil balm can be applied allows HCP to treat wounds that would be often problematic for the patient and could lead to patient non-compliancy. Revamil balm can support HCP in treating patients and speeding up the wound healing process. This in turn will help to reduce cost and medicinal wastage on local CCGs and Trusts and allow the patient, when applicable get back to work quicker.
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Case studies have been performed by Professor Steve Jeffrey, Burns and Plastics, Q.E Hospital, Birmingham, using Revamil gel in the treatment of several burns on a varied patient group.
 
These case studies have demonstrated the success of using Revamil balm dressings on a variety of burns patients within a hospital setting. The impact of such success can lead to patient’s wellbeing and health benefiting from quicker hospital discharge times as well as accelerated wound healing, reduced scaring and long-term psychological effects that stagnant painful wounds have on patients. Revamil balm dressing use can therefore support local health boards in cost efficiency and allow, where appropriate, an earlier return to work for the patient.
Current and planned activity: 
Currently underway:
  • Manchester Children’s Hospital – Trial of 50 patients (Burns)
  • Royal Preston Hospital – Trial burns unit (adults)
  • Stafford community – Trial tissue viability
  • Plymouth community – Trial tissue viability
  • Kent community – Trial tissue viability
We are looking for West Midlands partners to assist with a clinical evaluation to create UK outcome data taking a holistic view of the economic impact from a department (Trust) and patient perspecitive.

 
Return on Investment (£ Value): 
low
Return on Investment (Timescale): 
2 years
Ease of scalability: 
2
Read more
Hide details
Clare Chesworth 13/11/2019 - 15:37 Publish 2 comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
MediShout uses Apps and AI to turn hospitals in smart, automated buildings. Our technology prevents infra-structure and logistical problems (e.g. broken IT, missing stock, faulty equipment) from delaying staff who can focus more time on patient care.
Overview of Innovation:
THE PROBLEM 
IT, Equipment, Facilities, Estates, Stock... clinicians rely on these logistical Departments to deliver care, but often don’t report problems with them because:
1) Reporting-channels are too slow e.g. it often takes over 10 minutes to call a Helpdesk, and some Helpdesks get over 100,000 calls annually!
2) Staff don’t know how report issues as each Helpdesk has a different contact number, bleep, email etc
3) Sometimes NO reporting channel even exists
 
THE SOLUTION
MediShout solves this huge problem by giving staff a single-interface App to instantly report ANY logistical issue they encounter, such as broken IT or faulty equipment. Users simply select their ward, type their issue and press Shout. Our algorithms send this information to the correct administrator or Helpdesk who create change. Users can attach photos which helps Engineers fix problems faster. Two-way messaging and feedback provide regular updates to users on their issue.
 
MediShout captures data on the CLINICAL impact of each logistical problem reported; allowing hospitals to triage and fix the issues impacting patient care first. Our artificial-intelligence (machine-learning) algorithms can predict in advance when problems will occur, such as broken equipment, so hospitals can perform planned maintenance and prevent down-time in service provision.
 
BENEFITS
MediShout brings an excellent Return-on-Investment. Independent analysis by Health Enterprise East and Eastern AHSN, shows our platform can save NHS Trusts over £1million in efficiency savings per year. It can also generate direct cash-releasing savings, for example by requiring fewer administrative staff to operate Helpdesk telephones.

We improve the working environment and morale for staff, and can save 15 minutes per clinician daily.

Patient care improves as staff have more time with them. Our case studies also demonstrate faster patient discharges occurred from improved work-flow.
 
INNOVATIVE
MediShout is globally the first product to integrate all logistical Departments onto one platform, giving staff a quick single-interface App to report issues. We are the first to collect real-time data on the clinical impact of logistical issues whilst using AI to predict problems.

TRACTION
We've had traction across multiple Trusts in different regions plus acceptance by over 10 NHS hospitals and 2 pharmacies. We are on the NHS Clinical Entrepreneur programme, the WMAHSN Digital Health Accelerator and TechHub Accelerator.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Education, training and future workforce / Wealth creation / Digital health / Innovation and adoption
Benefit to NHS:
HEALTH ECONOMIC IMPACT

1. Cost-Savings 
Health Enterprise East Ltd (HEE) undertook an independent, retrospective economic evaluation of Medishout, based on the above data. To create a robust cost-saving estimation, HEE created a mathematical economic model combining the data available with NHS tariff and unit costs.
 
The outcomes demonstrated that MediShout can save NHS Trusts over £1million per year in efficiency savings. This is predominantly from reducing wasted resources and staff-time and would equate to approximately £200million for the NHS annually. Furthermore, our platform also makes cash-releasing savings e.g. needing fewer administrative staff to operate telephones, or cancelling fewer operations.
 
2. Improved Efficiency
a) Q Health’s analysis praised MediShout for eradicating “ward inefficiencies” by enabling staff “to connect their issue with the right person”
b) At Imperial, the ED Matron believes MediShout gives managers “a much more robust oversight of the issues affecting our service delivery”, which is allowing their Department to batch-fix issues like carpentry faults.
c) By receiving photos, Engineers assess problems in advance and attend jobs with correct tools
d) AI-algorithms predicting problems allows advanced equipment maintenance
 
3. Improved Workflow / Faster Discharges
A publication in Journal of mHealth demonstrated that MediShout led to improved use of IT resources, which resulted in faster patient discharges at Watford General.

IMPROVED EXPERIENCE FOR STAFF
 
4. Improved Workforce Efficiency
MediShout saves clinicians up to 15 minutes per day, by reducing issue-reporting from 10 minutes to 35 seconds.
 
5. Improve Staff Morale
MediShout improves morale as 97% of staff (87/90) felt MediShout gives them more time with patients and 100% of staff approved use of our app.

IMPROVED OUTCOMES FOR PATIENTS
 
6. Prioritise Issues Affecting Patient Care
MediShout helps hospitals to identify which issues are most affecting patient care, so these can be fixed first.
 
7. More Time With Staff
At the international EUSEM Conference, we showed MediShout saves staff-time which can be spent at the patient-bedside, checking results or communicating with families.
 
8. Better Stock
Having better stocked wards, for example Crash Trolleys or Drugs Cupboards, is vital for preventing medical catastrophes.
 
9. Mental Health Harm Reduction
MediShout is currently working with a Mental Health Trust, for our platform to virtually map ligature fixtures, thus reducing risk of patient suicide. 
Initial Review Rating
4.60 (1 ratings)
Benefit to WM population:
HEALTH ECONOMIC IMPACT

1. Cost-Savings 
Health Enterprise East Ltd (HEE) undertook an independent, retrospective economic evaluation of Medishout, based on the above data. To create a robust cost-saving estimation, HEE created a mathematical economic model combining the data available with NHS tariff and unit costs.
 
The outcomes demonstrated that MediShout can save NHS Trusts over £1million per year in efficiency savings. This is predominantly from reducing wasted resources and staff-time and would equate to approximately £200million for the NHS annually. Furthermore, our platform also makes cash-releasing savings e.g. needing fewer administrative staff to operate telephones, or cancelling fewer operations.
 
2. Improved Efficiency
a) Q Health’s analysis praised MediShout for eradicating “ward inefficiencies” by enabling staff “to connect their issue with the right person”
b) At Imperial, the ED Matron believes MediShout gives managers “a much more robust oversight of the issues affecting our service delivery”, which is allowing their Department to batch-fix issues like carpentry faults.
c) By receiving photos, Engineers assess problems in advance and attend jobs with correct tools
d) AI-algorithms predicting problems allows advanced equipment maintenance
 
3. Improved Workflow / Faster Discharges
A publication in Journal of mHealth demonstrated that MediShout led to improved use of IT resources, which resulted in faster patient discharges at Watford General.

IMPROVED EXPERIENCE FOR STAFF
 
4. Improved Workforce Efficiency
MediShout saves clinicians up to 15 minutes per day, by reducing issue-reporting from 10 minutes to 35 seconds.
 
5. Improve Staff Morale
MediShout improves morale as 97% of staff (87/90) felt MediShout gives them more time with patients and 100% of staff approved use of our app.

IMPROVED OUTCOMES FOR PATIENTS
 
6. Prioritise Issues Affecting Patient Care
MediShout helps hospitals to identify which issues are most affecting patient care, so these can be fixed first.
 
7. More Time With Staff
At the international EUSEM Conference, we showed MediShout saves staff-time which can be spent at the patient-bedside, checking results or communicating with families.
 
8. Better Stock
Having better stocked wards, for example Crash Trolleys or Drugs Cupboards, is vital for preventing medical catastrophes.
 
9. Mental Health Harm Reduction
MediShout is currently working with a Mental Health Trust, for our platform to virtually map ligature fixtures, thus reducing risk of patient suicide. 
Current and planned activity: 
1. We are on the NHS Clinical Entrepreneur Programme
2. We were previousl accepted to the WM AHSN Digital Health Acclerator
3. We have a commerical partnership with Eastern AHSN who have paid for our economic impact study
4. Our has been accepted by over 10 NHS hospitals
5. We are in discussions with many NHS hospitals in the London and East of England Regions
6. Our next natural step is to gain a footprint in the Midlands especially as our software developers (Bronze Labs) are Midlands based
What is the intellectual property status of your innovation?:
We own all our own IP including the source-code. Data we have derived with hospitals has been shared with freedom to use (although we must sometimes anonymise this)
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
2
Read more
Hide details
ASH KALRAIYA 08/11/2019 - 19:44 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
AposTherapy can reduce elective care waiting lists and costs significantly, whilst maintaining excellent clinical outcomes and patient satisfaction. For the CCG's/ Trusts with long waiting lists it will be a game changer.
Overview of Innovation:
AposTherapy technology is not new science. AposTherapy incorporates traditional concepts used in physiotherapy and surgery and puts it all into one easy to use device. AposTherapy methodology is based on changing the forces working on the joints and increasing proprioception through controlled instability. By doing this the biomechanics of movement can be changed whilst new/forgotton neuromuscular pathways can be formed.
For example, a patient who has medial knee osteoarthritis is likely to have varus knee alignment, increasing the adductor moment on the knee - therefore increasing pain and difficulty with movement/ weightbearing. AposTherapy can reduce this adductor moment to allow soft tissue around the joint to work in a more efficient way.
Gradually through frequent short daily usage (like slippers) the body will learn better improved movement patterns/ motor pathways, so even when not using AposTherapy the improvements will be maintained. This incorporates functional rehabilitation and self-management techniques.
 
Compliance to treatment is exceptionally high due to the immediate pain-relieving effects of the device.
The AposTherapy device is a footworn pair of shoes, with convex components in specific positions - depending on the patient’s mobility, irritability and severity of symptoms - so it is completely individual to each patient.
 
Patients are screened over the phone for suitability, and then fully assessed by a physiotherapist using internationally recognised PROMS, spatio-temporal gait analysis and traditional physiotherapy assessment techniques. If the treatment is a suitable option for the patient then they will enter into an initial year plan, with 5-6 follow ups spread across 12 months to work towards their goals. At each follow up all outcomes and the device are reassessed and progressed as required.
 
During follow up years we expect patients to receive follow ups for maintenance / continued improvements.
 
AposTherapy is both a Product and Service - as the device is only fully effective through attendance to follow ups and following a treatment programme. Throughout treatment, patients will receive ongoing advice on pain management and graded exercise.
 
Intended patient group size is at least 50% of patients who meet criteria for hip/ knee replacement surgery.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Education, training and future workforce / Wealth creation / Innovation and adoption / Person centred care
Benefit to NHS:
-Reduced spend in this pathway. If less patients are requiring hip and knee replacement surgeries - and are being treated at 1/3 of the cost of surgery then funds saved here can be diverted to other areas, improving other pathways and not just this one MSK pathway. It also means waiting lists for surgeries have a better chance of meeting 18 week pathways.
-Improves skills of the physiotherapist work force by teaching them specialist gait analysis skills, and the implementation of a new treatment.
-Reduced GP/ healthcare professional visits
-Reduces analgesics consumption/ prescription
-Help with the fight against increasing antibiotic intolerance by reducing the number of surgeries
- Reduce obesity by reducing lower limb joint pain in this population to allow them to be more active
-More free beds
- Reduce antibiotic use as reduced risks due to reduced surgeries.

For Patients:
-Significantly improved pain and function in the long term,
-Greater understanding of their condition and persistent pain
-Allowing for improved self management techniques.
-An overall improvement in Quality of Life
-Avoidance of surgery in many cases.
-Reduced need to visit GP/ healthcare professionals
-Reduced intake of analgesics
 
Initial Review Rating
3.40 (2 ratings)
Benefit to WM population:
AposTherapy is able to provide a long term solution to persistent pain conditions, a key part of this is the immediate change in symptoms that patients feel when using the device, encouraging them to comply with the pathway.
-Non invasive,
-Produces excellent clinical results
-Has high patient satisfaction
-Is 1/3 of the cost of surgery
-Doesn't have the risks of surgery
-Doesn't have the waiting lists of surgery
-Free's up funds from this population to be used in other areas
-Risk Model ensures that for patients who do defer to surgery (<25%, as low as 9%)- Apos provides a proportional refund
-The effect size of Apostherapy for the OA hip/knee population is comparable to joint replacement surgery
Current and planned activity: 
Bedfordshire and Greenwich CCG- via Circle Health - treatment is prescribed to patients with hip and knee osteoarthritis - Circa 450 patients - ongoing
MECCG - Treatment is available for patients with knee osteoarthritis - follow ups for the next 3 years - Circa 250 patients
In the private market we have a network of independent physiotherapy/ multidisciplinary clinics providing AposTherapy for any suitable MSK condition of the lower limbs and lower back pain.
What is the intellectual property status of your innovation?:
IP is owned by Apos Global Assets the parent company 
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
2
Read more
Hide details
seema odedra 16/10/2019 - 11:37 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
QbTest reduces delay to ADHD diagnosis, improves patient and family experience and saves significant clinical time required to rule in or rule out the disorder.  
Overview of Innovation:
QbTest is an FDA cleared objective testing system that simultaneously measures attention, impulsivity and motor activity, a core requirement of diagnostic criteria in both DSMV and ICD10.  After a 15-minute test, the individual patient’s performance is then compared to an age and sex-matched control group (n = 1307).  A comprehensive report is available on test completion. Reports are in a readily understandable format and outline whether a child is more active, impulsive and inattentive than a group of age and gender-matched controls (children without ADHD).

QbTest results in a more accurate and timely clinical diagnosis. This includes ruling out ADHD as well as confirming ADHD.
 
QbTest includes a Data Management System to help demonstrate clinical/service outcomes through automatically collected data and is underpinned by a Professional Training Programme for quality assurance.
 
In 2017, the EMAHSN supported the delivery of 1231 QbTests within different pathways in three Trusts across the East Midlands. Time from assessment to diagnosis was reduced by 153 days. Costs were reduced by 32% by releasing 20% of the clinical time (median figures). 85% of patients found the results helpful and 94% of clinicians reported greater understanding of patient’s symptoms.

 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Advanced diagnostics, genomics and precision medicine / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
ADHD affects approximately 4-8% of school-aged children and is characterized by symptoms of inattention, impulsivity and hyperactivity.
 
At present, the process for diagnosing ADHD extends over multiple steps.  Assessment is based on the clinician’s judgement, supplemented by subjective reports from parents, teachers and the young person.  These reports can be contradictory, incomplete and not returned within a timely manner leading to delays in diagnosis. 
 
Children in the UK wait 18 months (average) to obtain an accurate diagnosis. Multiple clinic visits over this period drive significant costs to the health service estimated at £23 million. These costs exclude wider healthcare system costs (school observations) and social and economic costs (parental work loss, parental stress-related illness and increased childcare expenses).  Quality of care is highly variable across England.
 
Patients: quicker diagnosis, so faster access to appropriate treatment or an alternative care pathway. Improved understanding of symptoms and communication with teachers/ schools.
 
Clinical staff: 
Increased satisfaction and confidence in decision-making and supports the delivery of the NICE recommended ADHD pathway for Children & Young People. Reduction in time to diagnosis, thus savings in consultation minutes and patients moved off caseload quicker, earlier treatment decisions.
 
Providers:
Reduced costs, staff efficiency and client (family) satisfaction. Reduction in numbers of patients being allocated to the wrong treatment pathway or misprescribed medication.
 
Commissioners:
Removes unnecessary outpatient appointments from the system with cost savings if risk/gain sharing agreed locally with providers resulting in new tariff.
 
Parents and schools:
Unintended benefits include quicker diagnosis resulting in faster SENCO / appropriate education support to prevent educational failure linked to ADHD.  Fewer appointments mean children miss fewer school hours and parents see reduced time off work.
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
There are 490,459 children aged between 6-18 years old within the West Midlands based on 2018 nomis data.  From experience in the EMAHSN Demonstrator project 0.4% of this population will be evaluated for ADHD each year, n = 1962 .  There will be a reduction of approximately 1 clinic visit required to rule in or rule out ADHD, significantly reducing delay to diagnosis and time to effective treatment.   Early intervention to treat and support patients and families with ADHD is proven to improve academic and social functioning and avert the potential development of further mental health conditions i.e. depression and anxiety and associated social costs.
 
There are approximately 18-21 NHS clinics managing ADHD in the West Midlands.  With a mean saving per year of £84K the estimated return on investment to Trusts will be approximately £1.5-1.7M/pa
 
A complete calculation of the NHS and Social benefits in the West Midlands will be possible through the Budget Impact Model – Nov 2019.
Current and planned activity: 
Qbtech is engaging directly with NHS Trusts through online marketing, social media campaigns, face to face meetings and demonstrations.  Qbtech and EMAHSN are also committed to a series of roadshows to support adoption and spread in each AHSN area.  An implementation toolkit, developed together with the EMAHSN will be complete by the end of November 2019, as will a budget impact model developed by KSSAHSN for use at a National, Regional, AHSN and Trust/clinic level.  The toolkit will include national context for ADHD and the fit with stategic prioririties, funding case preparation and submission, workforce planning and pathway optimisation and evaluation support.  We will also provide contacts for support, a communication package and FAQs.
What is the intellectual property status of your innovation?:
QbTest is proprietary and trademarked medical device wholly owned by Qbtech.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Read more
Hide details
Tony Doyle 14/10/2019 - 11:21 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
The TUC Safety Valve eliminates risk associated in treating patients requiring TUC by preventing inadvertent balloon inflation in the urethra thus preventing traumatic injuries which prove costly to both patient safety and health system expenditure.
Overview of Innovation:
Urinary catheter related injuries typically occur in patients when the catheter’s anchoring balloon is inadvertently inflated in the urethra instead of correct inflation in the urinary bladder. Approximately 1.3%-7% of patients receiving an indwelling catheter will sustain iatrogenic urethral trauma during the insertion process through inadvertent balloon inflation whilst misplaced in the urethra. Many more patients outside of the hospital setting (ie. community care) rely on TUC as part of their daily lives, thus the scale of the issue at large is under reported. Injuries are more common in vulnerable patient groups such as spinal cord injury patients, pregnant females with distorted urethral anatomy and elderly men dependent on long-term urinary catheters or supra-pubic catheters.
 
In 2016, a prospective study in two hospitals from Republic of Ireland over 6 months highlighted that 37 urethral injuries occurred across the two hospitals during the placement of 2,750 catheters resulting in a healthcare cost of €335,377 exclusive of long-term complications, outpatient care and medico-legal costs. There were an additional 330 bed days and 17 ICU days required as a direct result of these injuries. This resulted in a cost in excess of €122 per catheter placed in these hospitals to cover the costs of iatrogenic injuries caused during the procedures. In 2019, a follow up study from the 37 patients who received urethral injuries highlighted 2 patients died as a result of urethral trauma related to TUC.

The patent protected TUC Safety Valve, is a novel, innovative, clinically proven technology preventing the risk of inadvertent inflation of the Foley catheter retention balloon in a patient's urethra instead of the bladder, as intended. It uses a safety pressure relief valve to indicate misplacement of the retention balloon during catheterisation, eliminating urethral damage. Once the valve has “popped” it will automatically deactivate once the user ceases depressing the syringe plunger so that it functions effectively throughout the procedure. The flow restrictor prevents rapid inflation of the retention balloon (an act which has the potential to allow a portion of the fluid to bypass the pressure valve and cause partial inflation of the balloon even when mispositioned) in the urethra.

View articles:
https://doi.org/10.1007/s11845-014-1120-5
https://doi.org/10.1016/j.juro.2016.05.114
https://doi.org/10.1016/j.urology.2018.02.026
https://doi.org/10.1007/s00345-019-02775-x

 
Stage of Development:
Close to market - Prototype near completion and final form may require additional validation/evaluation and all CE marking and regulatory requirements are in place
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Innovation and adoption / Patient and medicines safety
Benefit to NHS:
Urinary catheterisation yields significant volume of iatrogenic injuries with serious short & long-term patient complications that have substantial financial, resource, and medico-legal implications. Such injuries lead to an increased burden on resources, inpatient/ICU beds and workforce in the NHS.

Up to 25% of all hospitalised patients undergo routine Trans-Urethral Catheterisation (TUC) during their stay. Many more patients outside of the hospital setting (ie. community care) rely on TUC as part of their daily lives, thus the scale of the issue at large is under reported. TUC is more challenging in male patients due to the tortuous anatomy of the male urethra and due to prostatic hyperplasia however this risk is not limited to male patients nor solely adult patients.
Another cost measurement to consider is medico-legal claims against health organisations. In a 2011 British Journal Urology International publication, between 1995 to 2009 in the NHS 493 urology related claims were closed with indemnity payment with an average of 35 successful claims per year. In all, £20,508,686 was paid out, averaging £41,599 per claim.

Assuming a conservative 0.55% incidence rate (lower than the studied incidence rate), using the example of an 1,800 bed capacity NHS Trust:
  • 21,600 catheterisations per annum @ £10 per catheter kit = £216,000
  • 118 urethral traumas per annum (21,600 catheterisations * 0.55% incidence rate)
  • (1053 additional bed days, 54.5 additional ICU bed days)
  • £948,542 in complication costs + £216,000 total catheter spend = £1,164,542
  • 21,600 TUC Safety Valve @ £15 = £324,000
  • Net Yearly Cost Reduced from £1,164,542 to £540,000 (catheter kit + TUC Safety Valve)
Complication costs relate directly to immediate care required to manage urethral injury complications ie. additional bed days and ICU days incurred.

Using a reference of 142,000 in the NHS, assuming the above 0.55% incidence rate:
  • 1,704,000 catheterisations per annum @ £10 per catheter kit = £17,040,000
  • 9,372 urethral traumas per annum (1,704,000 catheterisations * 0.55% incidence rate)
  • Average 35 medico-legal claims @ £41,599 = £1,455,965
  • £75,336,742 in complication costs (83,627 additional bed days, 4,325.5 ICU bed days)
  • + £17,040,000 total catheter spend
  • + £1,455,965 total medico-legal claim
  • = £93,832,707 total NHS catheter care spend per annum
  • 1,704,000 TUC Safety Valve @ £15 = £25,560,000
  • Net Yearly Cost Reduced from £93,832,707 to £42,600,000 (catheter kit + TUC Safety Valve)
 
Initial Review Rating
4.60 (2 ratings)
Benefit to WM population:
As the manufacturing organisation (Class Medical Ltd) aspires to grow and develop an organisational structure in the UK to further promote and enable adoption of the TUC Safety Valve in the UK and Internationally, there is potential for an office base to be located in the UK with recruitment of a sales/clinical engagement team, marketing persons and a small administration and logistics team. This could benefit the WM region should the company decide to locate their office base in the UK as WM is a central location with access to a good logistical network and access to a skilled workforce.

From a patient perspective, through delivering upon the NHS ethos ‘Do No Harm’ by preventing: unnecessary adverse events, short and long-terms complications, unplanned care episodes, avoidable trauma, inpatient admissions, referrals to A&E and morbidity, the health and safety of the overall WM population (whom require TUC as part of their care) enables a better health economy whilst also reducing the strain on services in the region allowing a more efficient service to be provided. This in turn aids the local economy and resources can be allocated more efficiently and effectively to better support the needs of the population.
 
Current and planned activity: 
The TUC Safety Valve is pending CE and FDA Approval, both of which are on schedule for December 2019 as the final benchmark testing of sterility (shelf life) is finalised.

Commercial launch will take place internationally in January 2020. In the meantime, MedTech Connect Ltd are acting on behalf of Class Medical Ltd in the UK and internationally in engaging with KOL's, regulatory bodies, healthcare organisations and health innovation partners to identify pathway to adoption.

In the UK, we are identifying with AHSN partners regional sites for clinical evaluation and engaging discussions with community healthcare providers highlighting the safety and cost burden Urethral Trauma secondary to TUC in order for the TUC Safety Valve to be considered as part of the catheterisation pathway for patients and an effective value proposition to be delivered. NICE have also selected the TUC Safety Valve for selection by the selection committee to move forward with relevant guidance.
 
What is the intellectual property status of your innovation?:
Class Medical has a strong IP position, and no other syringe or catheter exists in the EU for TUC that has any safety features. The IP currently resides with the University of Limerick. The TUC Safety Valve was granted patents in the USA in October 2016 and the EU in January 2018. The simplicity of the design makes it very difficult to replicate. Importantly, the IP covers the device interface parameters with the human body and rate of inflation preventing a false positive signal. Parameters patented make it extremely difficult for other syringe or catheter designs to operate in the design window.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
3
Read more
Hide details
James Wright 20/09/2019 - 09:02 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Quality Improvers are seeking to connect to their network and add value to their patients. Hexitime is an elegant solution to both. "Give an hour, get one back". 
Overview of Innovation:
The concept of healthcare timebanking was first proposed at the 2017 annual Q Community conference and followed up with learning from timebanks in public services which have united disenfranchised communities. Small scale pilots across the Q Community have left members inspired, better resourced and equipped with new ideas. These have subsequently contributed to a successful bid for seed funding by myself and co-founder John Lodge from the 2018 Health Foundation Q Exchange.

We now have a platform built and ready to conduct exchanges at www.hexitime.com

Observing the simple premise of reciprocity, timebanking uses a virtual currency for skills exchanges that can work at organisational, regional or national levels. It is a way to source the skills, energy and expertise of the Quality Improvement community without real money changing hands. All exchanges are for improvement work and exchanges are equitable (e.g. member ‘A’ is not worth more than member ‘B’). Every hour given is rewarded by 1 credit that can be redeemed in a subsequent exchange.

Timebanking principles
1. Money is not exchanged.
2. Exchanges are for improvement work.
3. Exchanges are equitable, with participants' time worth the same.
4. Support is exchanged around a system.
5. Time credits can be earnt, spent or donated between anyone.
6. The exchange belongs to the community.
7. Community members want to make improvements

Hexitime was launched on the 4th April 2019 and within a few weeks has attracted 150 members who have posted dozens of heartfelt requests and generous offers. We are having at least one exchange per week with rich learning for both donors and recipients of the exchange. This video shows the story of one such exchange.

We now need to grow the Hexitime community and cultivate exchanges on the platform whilst evaluating the value it brings. Our vision is that this disruptive way of working becomes a mainstream way of sharing experience and expertise by catalysing connections between healthcare professionals and service users with the intention to improve the service itself. 
Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Education, training and future workforce / Innovation and adoption
Benefit to NHS:
Hexitime supports the NHS 10-year plan in 4 key areas;
  • Workforce. Hexitime provides a practical way for the workforce to deliver on its commitments as outlined in Closing the Gap by finding the right improvement skills at the right time without having to resort to more expensive bank, agency or consultancy options.
  • Digital potential. For the first time Hexitime creates an open marketplace for the health system to share improvement skills. It uses the potential for cheaper more collaborative and joined up health services, in line with Secretary of State’s priorities and the thinking behind the newly formed NHSX.
  • Integrated care. Hexitime offers users a mechanism for sharing their skills across organizational boundaries for the benefit of improving services, which our case studies show.
  • Forming genuine partnerships between professionals and patients. Hexitime was co-designed with patients from the outset and now has system wide partners participating on the platform for coordinating patient led co-design.

Hexitime also supports the national healthcare improvement and leadership development framework Developing People – Improving Care in the way it supports systems by allowing leadership and improvement skills to transfer indiscriminately between national/regional/provider/patient level (see conditions 1-5).

When piloting this scheme, we discovered that some Quality Improvers had spare time and capacity through their salaried roles or corporate volunteering schemes, whilst others simply wanted to continually challenge themselves and learn from others. Indeed, with the government pledging in 2015 to entitle all public sector workers three days’ paid leave to undertake volunteering, the healthcare benefits of this peer exchange could be quite significant given the right support and conditions.

For now, we're confident that Hexitime will benefit the system by:
  • Offering a free alternative to expensive day-rate improvement resource.
  • Connecting the demands and capacity of our members.
  • Allowing patient representatives to join in improvement work.
  • Enabling members to share their skills, develop themselves and widen their network.
  • Being accessible to all members regardless of their profession, background or pay grade.
  • Increasing the Q Communities connectivity.
  • Providing practical opportunities to share learning and skills across traditional boundaries.
  • Steering the healthcare community towards collaboration.
Initial Review Rating
3.80 (1 ratings)
Benefit to WM population:
Giving time to, and connecting people within, a community can have a remarkable effect on personal well-being, preventing burnout and building community cohesion.

Hexitime gives members, and the organisation they work for, a free platform to exchange their skills for improvement – helping both professional development and improvement projects.

Exchanges might include mentoring and coaching, delivering presentations, patient safety advice, data analysis and evaluation, workshop facilitation, sharing resources, peer review, support pathway development and user perspectives, to name a few. 
Current and planned activity: 
After the initial funding from the Health Foundation (HF), we have maintained a relationship and will be submitting a final report on the establishment of the platfrom in 3 months time.

In the interim we have engaged with the HF supported Q Community and the wider Quality Improvement workforce, encouraging them individually to join the plaffrom and conduct exchanges. We now have dozens of hearfelt-requests and generous offers.

We have encouraged and have had interest from Patient Experience groups and organisations including Care Opinion who have expressed an interest in organisational membership and thereby acting as a conduit for patients involvement in QI projects.

We have approached leads in individual organisations about they could use the platform to easily move resources around their own organisation or local healthcare economy. Several have been intrigued by the idea and see the appeal of a disruptive system in which no money changes hands and is hence low in bureaucracy.
What is the intellectual property status of your innovation?:
"Hexitime" is trademarked.

The Hexitime.com platform has been developed by Made Open Ltd. 
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
2 years
Ease of scalability: 
Simple
Read more
Hide details
Hesham Abdalla 16/07/2019 - 20:35 Publish 1 comment
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Prep Shield has a gentle, non-restrictive central aperture to protect patient’s skin & tourniquet from damaging preparation solution leakage. Made from medical grade material & suitable for all size limbs.


 
Overview of Innovation:
Prep Shield is a disposable drape with central apertures for use in minor and major operations. Prep Shield protects the patient and tourniquet from potentially corrosive skin preparation solutions, blood, pus and other fluids.

Prep Shield is easy to use and prevents pooling of the prep solutions around or under the torniquet that could be a potential fire risk or irritant. The soft seal technology prevents seepage through to the drapes, protecting friable skin and rheumatoid patients from a potential reaction to adhesives or prep solutions.

Prep Shield can be easily removed by snipping the edge and tearing to the central aperture. 

Prep Shield is made from a flexible, lightweight, blue latex-free medical grade material, CE attested.

To view a demonstration visit: https://www.youtube.com/watch?v=RENACNX8SQE
To view the website visit: https://www.buddycover.com/prep-shield/ 

With an increasing ageing population, replacement knee surgery and lower limb amputations are becoming more prevalent.

Examples of where Prep Shield can be used:

1. 'The number of hip replacement operations on people aged under 60 has risen 76% in the last decade, NHS figures for England reveal. ... Demand for new hips across all ages has risen - there were 89,919 of the operations in 2004-05 and 122,154 in 2014-15.​'

2. 'Diabetes UK has shown that there were 26,378 lower limb amputations related to diabetes in England from 2014 to 2017, an increase of 19.4% from 2010-2013.​'
Ref:  https://www.diabetes.org.uk/about_us/news/lower-limb-amputations

3. 'There are approximately 5-6000 major lower limb amputations undertaken per year in the UK.'​
Ref:  http://www.christopherimray.co.uk/lowerlimb.htm
 
Prep Shield is available in sizes 20 to 90cm. Clean room prepared in boxes of 25 & 50, Prep Shield is significantly cheaper than other drapes @ £2.40 each, adhesive paper drapes cost £5.40 each.
 
Disposable: size 40 x 40cm non-restrictive and non-adhesive.
 
 
Stage of Development:
Close to market - Prototype near completion and final form may require additional validation/evaluation and all CE marking and regulatory requirements are in place
WMAHSN priorities and themes addressed: 
Innovation and adoption / Person centred care
Benefit to NHS:
NHS Benefits:

Prep Shield is easy to use and store. It is more cost effective and less bulky than traditional drapes. Prep Shield will keep the tourniquet protected for possible re-use.

Patient Outcomes: 

The patient's skin is protected from preparation fluids which are potentially corrosive, reducing skin irritation.

Efficieny improvements:

Prep Shield is quick and easy to use and remove
Initial Review Rating
2.40 (2 ratings)
Benefit to WM population:
Figures show increased prevalence of diabetes and its consquences in Pakistani, Bangladeshi and Indian communities. The West Midlands has the largest population of this ethnicty.  

https://digital.nhs.uk/data-and-information/publications/statistical/hea...

There were 25,312 amputations and 136,215 revascularisations, and 7543 cases were linked. The prevalence rate per 100,000 (95% confidence intervals) for amputation was 26.3 (26.0–26.6) with rates significantly higher in Northern England (North: 31.7; 31.0–32.3, Midlands: 26.0; 25.3–26.7). The odds of having an amputation with a revascularisation remained significantly higher in the North (OR 1.22; 1.13–1.33) even after controlling demographic and disease risk factors.'

Ref:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265106/
 
Current and planned activity: 
Protoype ready, successfuly used. Lead time for production 3 weeks.  
What is the intellectual property status of your innovation?:
Trade mark and design registered.  Licensed by Joanna Winslade to QOL Limited.
Return on Investment (£ Value): 
medium
Return on Investment (Timescale): 
1 year
Ease of scalability: 
Simple
Regional Scalability:
We have not implemented at scale, but is a easily scalable.  We would need to employ more staff, and scale increased production gradually. 
Measures:
Greater exposure and awareness within the operating theatre environment and purchase through procurement. 
 
Results.
 
Easy for the surgeon to use, disposable. Video attached.  Patient’s skin saved from corrosive preparation solutions, better patient outcome for tissue viability.
Adoption target:
  1. Initially within the UK, international adoption at a later date.
50% of the amputations undertaken within the ‘UK 5,000 to 6,000 per annum’  
Ref:  https://www.christopherimray.co.uk/lowerlimb.htm
50% of the70,000 knee replacement operations carried our each year in the UK
Ref:   https://www.nhs.uk/news/medical-practice/better-data-n
Read more
Hide details
Joanna Winslade 15/07/2019 - 16:04 Detailed Submission Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
BUDDY® waterproof covers protect limb wound dressings in the shower and bath. 
Overview of Innovation:
BUDDY® limb covers could save health professionals time when bathing patients at home, in hospital or in a care home because they can bathe normally and keep their wound dressings dry on both legs and arms, whether they be bandaged or stitched. The ability to bathe improves wellbeing and potentially allows the wound to heal more quickly. There are products on the market that cover wound dressings to keep them dry but in our opinion, none are as lightweight and gentle​.  

This submission's statistics focus on the major problem of diabetic limb ulcers and skin tears.

An increasing number of (1) & (2) diabetic and (3) elderly people have (4) compromised skin and leg ulcers. 

(1https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-audit/diabetes-prevention-programme-2017-18 “Who's affected. Venous leg ulcers are estimated to affect around 1 in 500 people in the UK, although they become much more common with age. It's estimated around 1 in 50 people over the age of 80 has one.”

(2) https://www.diabetes.org.uk/resources-s3/.../diabetes_in_the_uk_2010.pdf
In 2013, there were almost 2.9 million people in the UK diagnosed with diabetes. By 2025, it is estimated that more than 5 million people in the UK will have diabetes. ... It is estimated that 10% of people with diabetes will have a diabetic foot ulcer at some point in their lives.

(3) https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/articles/overviewoftheukpopulation/november2018#the-uk-population-is-ageing
By 2066 there could be an additional 8.6 million people aged 65 years and over in the UK.

(4) https://www.woundcareadvisor.com/no-more-skin-tears/amp/
"A reported 1.5 million skin tears occur in institutionalised adults each year, and that does not include tears that occur at home."


 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Wellness and prevention of illness / Clinical trials and evidence / Innovation and adoption / Person centred care
Benefit to NHS:
NHS Benefits:  

BUDDY® covers are available on the UK Drug Tariff for Primary Care.  Hospital patients wellbeing and health professionals could benefit if they were available for Secondary Care, potentially freeing hospital beds due to improved recovery times, fewer visits to the GP (5) & (6) and less risk of infection due to wet dressings.

(5https://www.england.nhs.uk/2019/01/missed-gp-appointments-costing-nhs-millions/
 "Each appointment costs an average of £30"

(6) https://patient.info/doctor/leg-ulcers-pro​/

Patient outcomes:  

Improved physical and mental wellbeing and recovery times, at home or in hospital with the ability to bathe independently.  Lesser occurence of painful re-dressing due to wet dressings, and reduced risk of infection. Potential for faster recovery and home return from hospital.

Efficiency and improvements:

Potential for reduced home visit time and hospital attendance for patients and health professionals.

Cost Effectiveness: 

Saving health professinals (7) time and money (8) & (9) re-dressing wounds, accelerating patient recovery time and wellbeing, and freeing-up hospital beds at a cost of £ 400 per day or more (10).  

(7) Time:  http://www.pssru.ac.uk/pub/uc/uc2010/uc2010_s10.pdf

(8) Cost:  http://www.pressureinjury.com/uk-wound-care-cost/

(9https://www.magonlinelibrary.com/doi/full/10.12968/jowc.2017.26.6.292 '"The patient care cost of an unhealed wound was a mean 135% more than that of a wound that heals (ranging from £698 to £3998 per patient for a healed wound versus £1719 to £5976 per patient for an unhealed wound)."

(10) ​https://www.linkedin.com › pulse › stay-hospital-bed-uk-costs-400-per-day-...


 
Initial Review Rating
3.80 (2 ratings)
Benefit to WM population:
Health:  With the increasing elderly population of 1.6 million (2017) (11)  in the West Midlands and the rise in diabetes (12), inevitably more patients will suffer from skin tears, pressure sores on limbs and leg ulcers.  According to diabetes.org.uk and Google, the ethnic mix of the West Midlands has a large Pakastani population (227,248 2011) who are 5 times more likely to have type 2 diabetes than the general population, the Bangladeshi population is 3 times more likely as are Indian population at 2.5 times more likely. 

(11) Elderly population: http://www.birmingham.gov.uk

(12) Diabetes:  http://www.england.nhs.uk/mids-east/2018/06/18
 
Current and planned activity: 
Currently supplied to pharmacies via Prescriptions.

Planned activity includes accessing smaller tenders for NHS Procurement and private hospitals and establishing a clinically based evidence trial for which we need support.  We are planning to develop waterproof covers for hips & shoulders.
What is the intellectual property status of your innovation?:
Trade mark BUDDY® registered along with product design rights licensed to QOL Limited by Joanna Winslade.
Return on Investment (£ Value): 
low
Return on Investment (Timescale): 
1 year
Ease of scalability: 
Simple
Regional Scalability:
We have not implemented at scale in any other region, but have the facility to do so. Upscaling will mean taking on more employees for administration.
Measures:
Outcomes:  Greater exposure of our products to relevant NHS purchasers, increased sales 
Interpretation of results:  Dry wound dressings & a clean comfortable patient with a reduced risk of infection from wet dressings & an improved quality of life. Within secondary care we understand a key national priority is to reduce the length of stay for day case patients having ACL reconstruction surgery. Enabling the patient to shower & bath in comfort & privacy (when mobility allows) wherever they are recovering.  

A customer feedback form (copy in downloaded documents above) based on the products effectiveness and usefulness to the patient.  Clear instructions for use are detailed on the product insert as downloaded above. 
 
Adoption target:
Targeting 10% of:
https://www.birminghammail.co.uk/news/midlands-news/shocking-number-diabetic-brummies-having-15795059
 280,912 Diabetics in West Midlands 2017/18
 ‘Equivalent to more than four amputations every week’
https://wmcanceralliance.nhs.uk
 '600 per 100,000 will have cancer'
34,800 patients.  A % of these will have chemotherapy 


 
Read more
Hide details
Joanna Winslade 15/07/2019 - 15:59 Detailed Submission Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
The MindHarp provides an engrossing, stimulating and active music-based activity addressing the typical behavioural and psychological symptoms of dementia (low self-esteem, social withdrawal, stress, depression). It is designed for any carer to use.
Overview of Innovation:
MindHarp is unique. It generates beautifully crafted musical sounds at the touch of a button. It’s a deeply rewarding and enriching activity engaging the player and carer physically, mentally and emotionally. It requires no learning, musical background or ability.
  1. Doesn’t require expensive, specialist facilitation or intervention (i.e. entertainers or music therapists)
  2. A wonderful bridge between ageing relatives, children, grandchildren and friendship groups
  3. Relaxing, stimulating, sociable, immersive and leads to all sorts of unexpected conversation, song and laughter
It was designed and developed over 12 months working directly with people living with dementia. It is now used regularly in care homes and by domestic carers via a new programme in the BANES carers Centre who loan out MindHarps.

It is currently available for iOS Apple iPads. (Android version available by end of 2019). It requires NO internet connection. The one-off price provides organisations with multiple downloads. It is fully supported with training and session guidance.

WHY IS MINDHARP IMPORTANT?
  • Less than 5% of care homes provide good quality arts and music provision (Utley/ILC report 2018)
  • It is a meaningful, adult activity that build bonds and connection between domestic carersand their loved ones /professional carers and  those being cared for
WHY MUSIC MATTERS – THE KNOWN BENEFITS
  • Firstly, there are no really definitive randomised control trials (RCTs) and more and better quality studies are required. However, the experiential and anecdotal evidence that music has a powerful and positive effect is overwhelming. There is much compelling evidence to support and suggest the use of music interventions has a direct effect on the psycho-social well-being of people living with dementia. We ourselves have much evidence in this regard.
  • We are seeking further support to participate in studies to definbitevely confirm:
    • Effects on BPSDs
    • Increased well-being of user and carer (enhanced moods, social participation, communication etc)

ALIGNMENT WITH GOVT PRIORITIES

The government wants to expand the use of music for dementia patients, as part of its drive to expand “social prescribing”. The NHS long-term plan, published in January 2019, promises to roll out social prescribing, including music and the arts. By April 2021, there will be over 1,000 trained social prescribing link workers and more in place by April 2024, with the aim that over 900,000 people are able to be referred to social prescribing schemes.

 

Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Wealth creation / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
As an engrossing, absorbing and creative activity, the MindHarp can be deployed in a number of ways:

1. AS A WELL-BEING TOOL
The MindHarp addresses all 3 acknowledged routes to well-being:
  •  Hedonic: An engrossing, calming, relaxing activity, reducing stress and anxiety. It is played for fun.
  • Eudemonic: More purposed, reflective with specific outcomes - this would include mindfulness-type training which is in development
  • Social: as an activity done in pairs or small groups

2. CURRENT EVALUATIONS

Dr Ed Carlton of the Southmead Hospital in Bristol is doing a pilot test to measure the MindHarp's impact on Dementia patients presenting in A&E (approx 3 per day). He is particularly interested in the MindHarp's ability to relax people prior to painful painrelieving injections.

Other Potential Applications:
  • In-Patients:
    • a cost effective activity for bored and stressed in-patients
    • a non-language/cultural and non-verbal activity - accessible to all irrespective of background or abilities
    • a valuable addition to the toolkit of those working in rehabilitation, requiring mental and physical stimuli (i.e.stroke recovery)
    • an activity for families and friends waiting around in hospital and also something they can do with their loved ones who have been admitted
  • For Staff:
    • As with carers in care settings, the MindHarp is an excellent de-stress tool for busy and stressed-out staff
  • Care in the Community:
    • For dementia, memory cafes, community groups etc
    • For mental health applications: children with ADHD, autism etc 
    • For bringing together disparate groups - social stimuli and social cohesion
Initial Review Rating
3.80 (2 ratings)
Benefit to WM population:
As above
Current and planned activity: 

1. With Dr Ed Carlton of the Southmead Hospital in Bristol is doing a pilot test to measure the MindHarp's impact on Dementia patients presenting in A&E (approx 3 per day). He is particularly interested in the MindHarp's ability to relax prior to painful pain relieving injections.

2. BANES Carers Centre. We have a funded trial underway working with the BANES (Bath and Northeast Somerset) Carers Centre. They have purchased 10 MindHarps and we are working with them to assess impacts on the well-being of the carer, their cared-for. (3 month trial). It includes a broader spectrum of carers delaing with conditions beyond dementia (i.e cerebral palsy, Parkinsons etc.)

2. NHS Dementia Wellbeing Service. Working with all community stakeholders  to work out ways to implement MindHarp across their activities - (homecare organisations, prison service, special needs)

3. Wiltshire CCG Mental Health Initiatives. Invited by the CEO to present and discuss and contribute to their evolving programme.
What is the intellectual property status of your innovation?:
We have Registered TM and legal protection over the musical sound content.
Return on Investment (£ Value): 
Very low
Return on Investment (Timescale): 
2 years
Ease of scalability: 
Simple
Read more
Hide details
Stewart Redpath 25/06/2019 - 17:08 Publish 3 comments
5
1
Votes
-99999
Innovation 'Elevator Pitch':
As experts in digitising clinical pathways, we empower patients and clinicians through our virtual outpatient clinic platform. Our work at Barts demonstrated 3x reduction in DNAs and 10 additional patients seen per 4-hour clinic.
Overview of Innovation:

Ortus-iHealth has developed a downloadable app for your smartphone and tablet. Within the app, the patient and carers can do the following:
  • Video Consultations
  • Record symptoms and health statistics
  • Set reminders for taking medicines
  • Manage appointments
  • Set tasks to achieve health goals
  • View clinic letters in a centralised place
  • Receive specific health-related information, research and more
  • Patient satisfaction surveys


All this data is then available to the clinician for review through an accompanying web portal. PROMS and PREMS questionnaires with actionable data analytics are easily generated. Finally, the portal allows for a secure, excellent quality virtual consultations to take place, from anywhere and at any time.

Please use this link for a video of the patient experience and see the attached user manual for a sense of the clinician portal and workflow. Please also feel free to use the following dummy logins to try it for yourself:

Patient Login
Email test+wmahsn_patient@ortus-ihealth.com
Password 16May2003
Access WebiOSAndroid

Clinician Login
Email test+wmahsn_clinician@ortus-ihealth.com
Password 16May2003
Access Web
 
Support Staff Login
Email test+wmahsn_support@ortus-ihealth.com
Password 16May2003
Access Web
 
All data is held on a secure server in the UK Cloud. Our product is data protection compliant and up to date with the latest information governance standards as set out in the latest DSP toolkit.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:

Increased efficiency
  • 4x reduction of ‘did-not-attends’ from 10-12% to 3% - applied across the NHS this would save £750bn
  • 10 additional patients seen per week due to additional capacity
  • 0 adverse events
  • In a remote monitoring clinic, 8 patients can be ‘seen’ in 30 minutes rather than 3 hours
  • In a video clinic with pre-filled questionnaires, 8 patients can be seen in 70 minutes rather than 3 hours


Patient savings
  • 100% saved money
  • 97% saved >30 minutes


Patient satisfaction
  • 90% satisfied with the virtual clinic experience
  • 100% found appointment reminders useful
  • 83% valued access to clinical letters
Initial Review Rating
3.40 (2 ratings)
Benefit to WM population:
Please see above
Current and planned activity: 
We are already working with Barts Health to scale up across multiple departments catering to 3000 patient interactions including in Cardiology, Cardiothoracics, Respiratory, General Surgery and Oncology.
What is the intellectual property status of your innovation?:
Ortus owns the IP.
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Dilraj Kalsi 29/04/2019 - 18:00 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
AR providing point of need access to support information, training advice and guidance in multiple areas including mental health
Overview of Innovation:
Our augmented reality (AR) materials offer the first phase of support - Instant, point of need, self-help techniques and early intervention strategies.  All resources include signposting to follow on professional support and information on long-term strategies to improve access to NHS digital support strategies and resources.  These should be implemented alongside our resources to provide a complete support mechanism for those at risk of suicide and dealing with mental health issues.
 
Key rings, Posters and other objects can be transformed from passive, physical, real world objects into an engaging augmented digital experience and boosting “mobile-first” engagement. 
Simply put, mobile phone users, through the use of an access app are able to scan a poster or symbol on a product and immediately access video, website content and/or directly contact an organisation for support.  This technology can be harnessed to help meet the objectives set out in NHS Long Term Plan in regards to the use of digital technology to help people better manage their health and achieve widespread digital access to training, information advice and guidance (IAG) and support.  With estimates that around 94% of adults in the UK owning a mobile and that around 86% of 12 to 18 year olds regularly use a mobile(Statista, 2019), there is no need for specialized and/or expensive equipment to be supplied to users to use AR technology.
 
Augmented Reality (AR) allows content to be easily modified based on identified needs.  It provides a scalable and cost effective digital model to connect patients with care.   By Incorporating AR into, for example, into a mental health campaign strategy the NHS can overcome social and physical hurdles associated with asking for help, seeking information and accessing the right care promptly.  AR could also potentially provide immediate access to professional advice and guidance, assist in preventing and providing early intervention access, providing them with ‘take-away’ information and/or swift access to support.
 
Along with national NHS strategy Augmented Reality content can provide fast support to people in their own homes with ‘same day care’ and point of need digital support via AR wearables linking to online ‘digital’ GP consultations and act as a further service expansion to regional prevention campaigns like the West Midlands Combined authority Thrive at Work helping to reduce outpatient appointments. (see additional information)
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
We have found that 94% of adults own a mobile (up from 82% in 2005), and that around 86% of 12 to 18 year olds regularly use a mobile. The 55-75 year old age group are the fastest growing adopters of smartphones over the last 5 years. (Statista 2018).[SA1] 
 
We will use Augmented Reality (AR) to provide a discreet, immediate and anonymous route to relevant mental health support resources with the need for services to provide equipment for access.
 
Enlighten’s augmented reality solutions are a simple, user friendly way to meet some of the initiatives set out in the NHS long term plan. They are particularly relevant to plans centered around research and innovation to “drive future medical advance, with the NHS committing to play its full part in the benefits these bring both to patients and the UK economy”. They can save significant amounts of money on fewer lost sick days through mental ill health and by reducing waste and lowering the carbon footprint of the NHS by minimising the need to print out large quantities of materials.
 
Over the next ten years they will result in an NHS where digital access to services is widespread. Where patients and their carers can better manage their health and condition. Where clinicians can access and interact with patient records and care plans wherever they are, with ready access to decision support and AI, and without the administrative hassle of today.
 
Content provided will tie into the mental health focus areas by offering; tools and techniques to self-manage mental health conditions, routes to local support services, guidance for supporting somebody with a mental health condition and the workplace mental health policy/strategy to raise awareness and reduce stigma.
 
This pocket-sized technology provides instant access to support through users own smart devices raising the awareness of various mental health issues in an accessible and inclusive way, reducing the stigma attached through familiarization.
 
Additional benefits will include staff and users exposure to modern, Web 2.0 ideas regarding use of appropriate technologies including the potential use of AR video evidence and BYOD.
Benefits derived from this approach include:
  • Improving user experience whilst driving up quality and standardisation
  • Maximising use of electronic resources
  • A standardised package of AR resources to reuse within the NHS
Initial Review Rating
4.00 (2 ratings)
Benefit to WM population:
As identified in the “Improving lives: The future of Work, Health and Disability”, employers can only help someone start or stay in work if they are aware of a mental health condition. Key findings nationally show that only 11% of employees discussed a recent mental health problem with their line manager, half of employees said they would not discuss mental health with their manager and only 24% of managers have received some form of training on mental health at work (Business in the Community, Mental Health at work Report 2017). From the statistics and our work with employers, we can see that there is further support required to address this gap. We will provide tools for employees and upskill employers to encourage better dialogue and workplace environments where:
 
  • Employees feel more able to disclose mental health conditions, access support and self-manage their conditions, allowing them to remain in work.
  • Employers have a greater awareness of the needs of their workforce and what support and resources are effective and engaging.
  • Both employees and employers are aware of local support services and have instant easy and discreet access to contact details.
Line managers and HR departments are skilled in understanding how to support colleagues disclosing mental health conditions.
Current and planned activity: 
  • In 2020, we plan to implement the output made possible with support from this project funding and verify its effectiveness through a demonstrative project with 1 x UK Smart City.
What is the intellectual property status of your innovation?:
Currently in discussions with IP experts 
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
2
Read more
Hide details
Suzanne Edwards 13/03/2019 - 15:49 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
ReferBack™ is a secure electronic specialist referral system that standardises the referral process, improves patient care, helps clinicians avoid unnecessary risk, interfaces with the BSR and saves time and money for the clinician and the NHS.
Overview of Innovation:
ReferBack™ provides a simple and secure electronic referral platform that allows medical teams to connect to specialists to assess conditions; refer critical patients and gain advice on treatment options for urgent cases. 
ReferBack™ has been developed by Amplitude in conjunction with leading spine surgeons in the UK; is endorsed by the British Association of Spine Surgeons and links directly to The British Spine Registry. 

Developed specifically for urgent spine and neuro referrals, the system is pre-populated with precise clinical questions and options that specialists require to make their assessment. 

Information is requested in structured forms and clinical questionnaires, relevant to the patients presenting problems. This allows a speedier in-put and selection of symptoms, co-morbidities, test results and observations, needed to gain a whole picture view. This process ensures thorough and consistent patient evaluations.
Patients and hospitals are no longer exposed to the consequences of unstructured and untraceable communications. All communications are tracked and traceable, so patients are not "lost" in the referral process.

ReferBack™ automatically notifies clinicians when a new referral has been received and when advice has been returned via text message, so that "downtime" between teams during any on-going communications is minimised. Communication continues until patient management decisions are agreed.

Clinical administration is simplified and reduced. Additionally, the system interfaces with the British Spine Registry (BSR), reducing the need for duplicate data entry, as the patient is on-boarded directly to the BSR. The use of an electronic emergency referral system and contribution to the BSR was highlighted as best practice recommendations in the 2019 Spinal Services GIRFT Programme National Specialty Report.

In 2016/17 the cost of medical negligence claims against spinal surgery was £135.1 million. Over 75% of these claims were due to ‘judgement / timing’ (512 claims, 52.35%), ‘interpretation of results / clinical picture’ (255 claims, 26.07%). All communications in ReferBack™ are tracked and traceable and can be used in any future litigation queries made about the quality of care received.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Digital health / Innovation and adoption
Benefit to NHS:
ReferBack™ is an electronic emergency referral system that was developed in collaboration with a leading spine surgeon, is endorsed by the British Association of Spine Surgeons and uploads directly to the British Spine Registry. It costs less than £100 per week, less than half the main competitor in the market.

From April 2019, all spine services in England are required to submit spine surgery data to the British Spine Registry in order to achieve best practice tariff, which equates to 10% of their department’s annual budget. The automated push of this data to the British Spine Registry ensures best practice tariff is achieved.

The simple to use, cloud-based software contains structured clinical questionnaires that allow fast input, ensuring complete information is captured and sent to the hub, who are then able to fully assess the patient from the outset.

Referrals use structured datasets to guide the referrer to ensure the data entered is complete and sufficiently detailed to allow the hub to properly assess the patient, resulting in thorough and consistent patient evaluations.
The system automatically notifies clinicians by SMS when a new referral has been received and when advice has been returned so that “downtime” between teams during any on-going communications is minimised, until patient management decisions are agreed. 

All communications are tracked and auditable. When a new clinician starts their shift, they can easily see any outstanding referrals and their status. The initial referral and any additional interaction between teams is documented and time stamped, helping Trusts to mitigate against future spinal litigation.

The system improves the speed of referral service being delivered ultimately improving the quality of care received by the patient. By using structured datasets, a complete picture is available from the initial referral, ensuring all information, including co-morbidities, are considered, resulting in a reduced risk of long-term complications.

In February 2019, GIRFT (Getting It Right First Time – NHS England initiative for best practice) released their Report into Spinal Services, in which they recommend the implementation of an electronic emergency referral system. ReferBack™ allows organisations to follow these GIRFT recommendations and by default, this electronic system digitises the entire referral process, reducing clinical admin and ensuring the records are accurate and less liable to mis-interpretation.
Initial Review Rating
4.40 (2 ratings)
Benefit to WM population:
ReferBack™ was trialled at Royal Devon and Exeter and at Sheffield Teaching Hospitals NHS Foundation Trust.
Both pilots offered a testing environment that was similar to environments that could easily be replicated throughout the UK including the Trusts as set up in the West Midlands. There are 7 feeder hospitals for RD&E and 9 for STH, a set-up that would be similar to the midlands-based Spine Hubs.

There are 8 Trusts identified in the 2019 GIRFT report for Spinal Services as specialised providers of complex spinal surgery in the midlands.
  • Derby Teaching Hospitals NHS Foundation Trust
  • Nottingham University Hospitals
  • The Robert Jones and Agnes Hunt Orthopaedic Hospital NHs Foundation Trust
  • The Royal Orthopaedic Hospital NHS Foundation Trust
  • University Hospitals Birmingham NHS Foundation Trust
  • University Hospitals Coventry and Warwickshire NHS Trust
  • University Hospitals of Leicester NHS Trust
  • University Hospitals of North Midlands NHS Trust
All of which take referrals from feeder hospitals and are expected to submit to the British Spine Registry to maintain best practice tariff compliance and would benefit from ReferBack™ as an electronic emergency referral system.

The software is designed for a fast deployment into NHS Spine Hubs for future users of the system. Implementation can be within a week, including system training. It is self-regulating, meaning the clinical lead at the Spinal Hub approves the registration of new clinicians using the system. There are many mandatory fields that prescribe the minimum information required by the spine specialist team to make an accurate assessment. These were outlined during the research and development stages of the system design and remain the same in all platform deployments. These are managed by the group of senior spine surgeons that make up the development steering committee.

Although originally designed for spinal services, the system can be applied to any specialty and would benefit any specialty whereby time was a crucial element to safe delivery of care. I.e. Cardiology, Neurology, Stroke, Paediatric Trauma and others.

In addition, the system is now being developed to assist referrals in oncology, whereby MDT meetings review patients from greater geographic areas than just the local Trust with no single patient management system or platform, in all referring hospitals.
 
Current and planned activity: 
ReferBack™ recently exhibited at the BASS Annual Congress and was recommended by its executive committee. Several Trusts are now taking advantage of the 1-month free trial offer available, to test the system in their environment.

We are finalising the Cranial Pathway to be added to the Spine Pathway meaning that orthopaedic and neuro / cranial referrals can all be managed in the one system.

There is continual development on the system, continually taking on board requests from the system users to improve functionality by adding areas including detailed reporting.
What is the intellectual property status of your innovation?:
Amplitude Clinical Outcomes owns the intellectual property copyright of the innovation. BASS assisted in the development of the system with the understanding that it would be sold at a cost that covers the development plus the ongoing upkeep and development. This has enabled the system to enter the market at 1/2 the cost of the existing product, that has less functionality and does not upload directly to the BSR.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
1 year
Ease of scalability: 
Simple
Read more
Hide details
Sarah Steptoe 11/02/2019 - 14:47 Publish Login or Register to post comments
0
0
Votes
-99999

Recent Activities

MediShout has been moved from Initial Submission to Publish 1 month 2 weeks ago
Brain in Hand: a personalised digital support system for organisation, anxiety, memory, and problem-solving has been moved from Initial Submission to Publish 1 month 2 weeks ago
Brain in Hand: a personalised digital support system for organisation, anxiety, memory, and problem-solving has been moved from Initial Submission to Publish 1 month 2 weeks ago
Thomas Hughes voted on Dementia Dekh Bhaal 2 months 15 hours ago
Thomas Hughes voted on Knowing Me! 2 months 16 hours ago

Active Campaigns